The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Q1 2025 Management View CEO Bernard Zovighian outlined that total company sales grew 8% to $1.41 billion in Q1 2025, driven ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

The U.S. Medicare draft inpatient rule for fiscal 2026 discusses a number of coding proposals, although the agency seems disinclined to go along with a proposal to increase payment rates for TAVR ...

At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement and surgery in patients at low surgical risk. Both groups had improvements in ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...